| Stefan Barry Zweig, DPM | |
|
1785 E Main St, Suite 3, Dothan, AL 36301-3045 | |
| (334) 793-6803 | |
| (334) 793-6803 |
| Full Name | Stefan Barry Zweig |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 44 Years |
| Location | 1785 E Main St, Dothan, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457458408 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0131X | Podiatrist - Foot Surgery | 98 (Alabama) | Primary |
| Provider Name | Foot Clinic Of Dothan, Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1558634170 PECOS PAC ID: 0446457865 Enrollment ID: O20120612000437 |
News Archive
A combination of two drugs - one of them an immunotherapy agent - could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
In a recent study from University of Gothenburg, it has been shown that all participants achieve normalization of CNS injury biomarkers, regardless of previous disease severity or persistent neurological symptoms. Indicating that post-COVID-19 neurological sequalae are not due to active brain injury.
To combat the nation's number one cancer killer, non-profit organizations Protect Your Lungs and LUNGevity Foundation today announced they will join forces in an effort to fund research and hope for a cure for lung cancer. Together, the new organization hopes to create the same successful improvements for lung cancer mortality rates as those experienced by breast, prostate, and colon cancer. The merged organization, committed to elevating lung cancer on the national agenda, will operate under the name LUNGevity Foundation with offices in Washington, D.C. and Chicago.
On Oct. 15, SynCardia Systems, Inc., manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, announced that its new Companion Driver System has received CE Mark approval to power the Total Artificial Heart in Europe.
Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.
› Verified 9 days ago
| Provider Name | Southeastern Family Foot Care Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1033457106 PECOS PAC ID: 0840436960 Enrollment ID: O20130416000480 |
News Archive
A combination of two drugs - one of them an immunotherapy agent - could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
In a recent study from University of Gothenburg, it has been shown that all participants achieve normalization of CNS injury biomarkers, regardless of previous disease severity or persistent neurological symptoms. Indicating that post-COVID-19 neurological sequalae are not due to active brain injury.
To combat the nation's number one cancer killer, non-profit organizations Protect Your Lungs and LUNGevity Foundation today announced they will join forces in an effort to fund research and hope for a cure for lung cancer. Together, the new organization hopes to create the same successful improvements for lung cancer mortality rates as those experienced by breast, prostate, and colon cancer. The merged organization, committed to elevating lung cancer on the national agenda, will operate under the name LUNGevity Foundation with offices in Washington, D.C. and Chicago.
On Oct. 15, SynCardia Systems, Inc., manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, announced that its new Companion Driver System has received CE Mark approval to power the Total Artificial Heart in Europe.
Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stefan Barry Zweig, DPM 1785 E Main St, Suite 3, Dothan, AL 36301-3045 Ph: (334) 793-6803 | Stefan Barry Zweig, DPM 1785 E Main St, Suite 3, Dothan, AL 36301-3045 Ph: (334) 793-6803 |
News Archive
A combination of two drugs - one of them an immunotherapy agent - could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
In a recent study from University of Gothenburg, it has been shown that all participants achieve normalization of CNS injury biomarkers, regardless of previous disease severity or persistent neurological symptoms. Indicating that post-COVID-19 neurological sequalae are not due to active brain injury.
To combat the nation's number one cancer killer, non-profit organizations Protect Your Lungs and LUNGevity Foundation today announced they will join forces in an effort to fund research and hope for a cure for lung cancer. Together, the new organization hopes to create the same successful improvements for lung cancer mortality rates as those experienced by breast, prostate, and colon cancer. The merged organization, committed to elevating lung cancer on the national agenda, will operate under the name LUNGevity Foundation with offices in Washington, D.C. and Chicago.
On Oct. 15, SynCardia Systems, Inc., manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, announced that its new Companion Driver System has received CE Mark approval to power the Total Artificial Heart in Europe.
Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.
› Verified 9 days ago
Benjamin J. Werner, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1500 Ross Clark Cir, Dothan, AL 36301 Phone: 334-793-2663 Fax: 334-836-2248 | |
Lisenby Podiatry Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1550 E Main St, Dothan, AL 36301 Phone: 334-671-1441 Fax: 334-671-1688 | |
Mary Diane Collier, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 204 Luds Way, Dothan, AL 36303 Phone: 334-678-7036 Fax: 334-702-4208 | |
Dr. David Russell Wuertzer, D.P.M. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1550 E Main St, Dothan, AL 36301 Phone: 334-792-3922 Fax: 334-712-0405 | |
Foot Clinic Of Dothan, Inc. Podiatrist Medicare: Medicare Enrolled Practice Location: 1785 E Main St, Suite 3, Dothan, AL 36301 Phone: 334-793-6803 Fax: 334-793-6803 | |
Brian C Melley Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1550 E Main St, Dothan, AL 36301 Phone: 334-671-1441 |